Literature DB >> 29078882

Safety and efficacy of combined resection of colorectal peritoneal and liver metastases.

Stephanie Downs-Canner1, Yongli Shuai2, Lekshmi Ramalingam1, James F Pingpank1, Matthew P Holtzman1, Herbert J Zeh1, David L Bartlett1, Haroon A Choudry3.   

Abstract

BACKGROUND: To determine if a select subgroup of patients with combined liver and peritoneal colorectal metastases would derive oncologic benefit from surgical resection as a component of multimodality treatment.
MATERIALS AND METHODS: We retrospectively compared 32 patients with combined colorectal peritoneal and liver metastases (CRLM) and 173 patients with peritoneal metastases only (CRPM) undergoing cytoreductive surgery with hyperthermic intraperitoneal chemoperfusion (CRS-HIPEC). Kaplan-Meier survival curves and multivariate Cox-regression models identified prognostic factors affecting survival.
RESULTS: Major postoperative complications (Clavien-Dindo grades 3-5) occurred in 32% (CRLM) and 17% (CRPM) of patients (P = 0.08). After an estimated median follow-up from surgery of 57 mo, propensity score-adjusted median progression-free survival was 5.1 mo (CRLM) and 7.6 mo (CRPM), whereas median overall survival was 13 mo (CRLM) and 21 mo (CRPM). Multivariate Cox-regression analysis of the CRLM group identified number of liver metastases to be the only independent predictor of poor survival (hazard ratio: 2.3, P = 0.03), with a dramatic decrease in survival in patients with more than three liver metastases.
CONCLUSIONS: Simultaneous resection of colorectal liver metastases at the time of cytoreductive surgery with hyperthermic intraperitoneal chemoperfusion for peritoneal metastases may be associated with worse survival, especially in patients with more than three liver metastases.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; Cytoreductive surgery; HIPEC; Metastases

Mesh:

Year:  2017        PMID: 29078882      PMCID: PMC5663460          DOI: 10.1016/j.jss.2017.05.126

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  33 in total

1.  Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.

Authors:  Jan Franko; Qian Shi; Charles D Goldman; Barbara A Pockaj; Garth D Nelson; Richard M Goldberg; Henry C Pitot; Axel Grothey; Steven R Alberts; Daniel J Sargent
Journal:  J Clin Oncol       Date:  2011-12-12       Impact factor: 44.544

2.  Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer.

Authors:  Rodrigo Gomes da Silva; Paul H Sugarbaker
Journal:  J Am Coll Surg       Date:  2006-10-25       Impact factor: 6.113

3.  Surgical resection for lung metastases from colorectal cancer.

Authors:  Hyung Jin Kim; Bong-Hyeon Kye; Jae Im Lee; Sang Chul Lee; Yoon Suk Lee; In Kyu Lee; Won Kyung Kang; Hyeon-Min Cho; Seok Whan Moon; Seong Taek Oh
Journal:  J Korean Soc Coloproctol       Date:  2010-10-31

4.  Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.

Authors:  O Glehen; F Kwiatkowski; P H Sugarbaker; D Elias; E A Levine; M De Simone; R Barone; Y Yonemura; F Cavaliere; F Quenet; M Gutman; A A K Tentes; G Lorimier; J L Bernard; J M Bereder; J Porcheron; A Gomez-Portilla; P Shen; M Deraco; P Rat
Journal:  J Clin Oncol       Date:  2004-08-15       Impact factor: 44.544

5.  Outcomes associated with cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in colorectal cancer patients with peritoneal surface disease and hepatic metastases.

Authors:  Oliver Varban; Edward A Levine; John H Stewart; Thomas P McCoy; Perry Shen
Journal:  Cancer       Date:  2009-08-01       Impact factor: 6.860

6.  Actual 10-year survival after resection of colorectal liver metastases defines cure.

Authors:  James S Tomlinson; William R Jarnagin; Ronald P DeMatteo; Yuman Fong; Peter Kornprat; Mithat Gonen; Nancy Kemeny; Murray F Brennan; Leslie H Blumgart; Michael D'Angelica
Journal:  J Clin Oncol       Date:  2007-10-10       Impact factor: 44.544

7.  Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.

Authors:  Dominique Elias; Jérémie H Lefevre; Julie Chevalier; Antoine Brouquet; Frédéric Marchal; Jean-Marc Classe; Gwenaël Ferron; Jean-Marc Guilloit; Pierre Meeus; Diane Goéré; Julia Bonastre
Journal:  J Clin Oncol       Date:  2008-12-22       Impact factor: 44.544

8.  Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.

Authors:  Grace K Dy; James E Krook; Erin M Green; Daniel J Sargent; Thierry Delaunoit; Roscoe F Morton; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Barbara A Pockaj; Robert P Sticca; Steven R Alberts; Henry C Pitot; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2007-08-10       Impact factor: 44.544

Review 9.  Colorectal cancer.

Authors:  Hermann Brenner; Matthias Kloor; Christian Peter Pox
Journal:  Lancet       Date:  2013-11-11       Impact factor: 79.321

Review 10.  Surgical techniques in visceral resection and peritonectomy procedures.

Authors:  Philip Bao; David Bartlett
Journal:  Cancer J       Date:  2009 May-Jun       Impact factor: 3.360

View more
  6 in total

1.  Quality Standards for Surgery of Colorectal Peritoneal Metastasis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Authors:  Alfonso García-Fadrique; Rafael Estevan Estevan; Luis Sabater Ortí
Journal:  Ann Surg Oncol       Date:  2021-08-25       Impact factor: 5.344

Review 2.  [Surgical treatment of peritoneal metastases of colorectal cancer].

Authors:  S Schüle; H Mothes; U Settmacher; J Zanow
Journal:  Chirurg       Date:  2018-09       Impact factor: 0.955

3.  Impact of Synchronous Liver Resection on the Perioperative Outcomes of Patients Undergoing CRS-HIPEC.

Authors:  Jordan M Cloyd; Sherif Abdel-Misih; John Hays; Mary E Dillhoff; Timothy M Pawlik; Carl Schmidt
Journal:  J Gastrointest Surg       Date:  2018-04-30       Impact factor: 3.452

4.  Definition and Prediction of Early Recurrence and Mortality Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: Towards Predicting Oncologic Futility Preoperatively.

Authors:  Caroline J Rieser; Heather Jones; Lauren B Hall; Eliza Kang; Shannon Altpeter; Amer H Zureikat; Matthew P Holtzman; Andrew Lee; Melanie Ongchin; James F Pingpank; M Haroon A Choudry; David L Bartlett
Journal:  Ann Surg Oncol       Date:  2021-07-05       Impact factor: 5.344

5.  A novel preoperative risk score to optimize patient selection for performing concomitant liver resection with cytoreductive surgery/HIPEC.

Authors:  Rachel M Lee; Adriana C Gamboa; Michael K Turgeon; Mohammad Y Zaidi; Charles Kimbrough; Jennifer Leiting; Travis Grotz; Andrew J Lee; Keith Fournier; Benjamin Powers; Sean Dineen; Joel M Baumgartner; Jula Veerapong; Harveshp Mogal; Callisia Clarke; Gregory Wilson; Sameer Patel; Ryan Hendrix; Laura Lambert; Courtney Pokrzywa; Daniel E Abbott; Christopher J LaRocca; Mustafa Raoof; Jonathan Greer; Fabian M Johnston; Charles A Staley; Jordan M Cloyd; Shishir K Maithel; Maria C Russell
Journal:  J Surg Oncol       Date:  2020-10-01       Impact factor: 3.454

6.  Clinical outcomes of complete cytoreduction with concurrent liver resection followed by hyperthermic intraperitoneal chemotherapy for synchronous peritoneal and liver metastatic colorectal cancer.

Authors:  Youngbae Jeon; Eun Jung Park; Jin Hong Lim; Seung Hyuk Baik
Journal:  World J Surg Oncol       Date:  2019-12-11       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.